Verition Fund Management
ALXN

Verition Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Verition Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-59,900
Closed -$11M – 2523
2021
Q2 		$11M Sell
59,900
-90,000
-60% -$15.4M 0.1% 126
2021
Q1 		$22.9M Buy
149,900
+32,600
+28% +$5.04M 0.26% 49
2020
Q4 		$18.3M Buy
117,300
+105,200
+869% +$13.5M 0.16% 96
2020
Q3 		$1.39M Buy
+12,100
New +$1.31M 0.03% 314

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Verition Fund Management's ALXN Position: Q3 2021 in Review

Verition Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 380,182 shares — an estimated $69.8M sold.

Verition Fund Management first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $69.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Verition Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Verition Fund Management sold 380,182 Alexion Pharmaceuticals shares in Q3 2021, an estimated $69.8M.
  • Verition Fund Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Verition Fund Management's Alexion Pharmaceuticals position peaked at $69.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Verition Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.